

## Drug Monograph

Drug/Drug     **Aggrastat<sup>®</sup> (tirofiban) solution for injection/**  
Class:           **Cardiovascular Agents**  
Prepared for: MO HealthNet  
Prepared by: Conduent

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Aggrastat<sup>®</sup> is now available in a bolus vial containing 3.75 mg tirofiban per 15 ml solution.

**Manufacturer:** Baxter Healthcare Corporation, Deerfield, Ill 60015

**Indications:** Aggrastat<sup>®</sup> is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome.

**Costs:** \$222.45 per 15 ml vial of Aggrastat<sup>®</sup>. Wholesale Acquisition Cost

**Summary of Findings:** MO HealthNet Division recommends Open Access status for this product.

**Status Recommendation:**      Prior Authorization (PA) Required      Open Access  
    Fiscal Edit    PDL

**Type of PA Criteria:**            Increased Risk of ADE    Under Solicitation  
    Appropriate Indications    No PA Required

Prepared By: Luke Boehmer Pharm.D.  
Date: February 22, 2017